Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1615
http://purl.obolibrary.org/obo/NCIT_C1615
|
|---|---|
| Preferred Name | Elinafide |
| Definitions |
A symmetrical dimeric bis-naphthalimide compound and a topoisomerase II inhibitor with antineoplastic activity. Elinafide contains two neutral chromophores joined by a cationic linker and is capable of bis-intercalation at the TpG and CpA steps of the DNA hexanucleotide. Intercalation inhibits topoisomerase II activity and causing DNA stand breakage, thereby leads to inhibition of DNA, RNA, and protein synthesis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A symmetrical dimeric bis-naphthalimide compound and a topoisomerase II inhibitor with antineoplastic activity. Elinafide contains two neutral chromophores joined by a cationic linker and is capable of bis-intercalation at the TpG and CpA steps of the DNA hexanucleotide. Intercalation inhibits topoisomerase II activity and causing DNA stand breakage, thereby leads to inhibition of DNA, RNA, and protein synthesis. |
|---|---|
| prefLabel | Elinafide
|
| label | Elinafide
|
| PDQ_Closed_Trial_Search_ID | 42578
|
| code | C1615
|
| prefixIRI | NCIT:C1615
|
| in_subset | |
| Preferred_Name | Elinafide
|
| FDA_UNII_Code | HL580335SI
|
| Contributing_Source | FDA
|
| Chemical_Formula | C31H28N4O4
|
| Maps_To | Elinafide
|
| CAS_Registry | 162706-37-8
|
| NCI_Drug_Dictionary_ID | 42578
|
| Legacy Concept Name | LU_79553
|
| type | |
| ALT_DEFINITION | An anticancer drug that kills cancer cells by affecting DNA synthesis.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 42578
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C1433453
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |